Stay updated with breaking news from Xiaohua Wu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 -- HUTCHMED Limited today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be...
Investegate announcements from HUTCHMED Presentations at 2024 ASCO Annual Meeting
The combination comprised of camrelizumab and famitinib showcased improved efficacy with a manageable safety profile vs camrelizumab monotherapy or investigator’s choice of chemotherapy in patients with recurrent or metastatic cervical cance.
Senaparib maintenance improved progression-free survival in patients with advanced ovarian cancer in a phase 3 trial.
The phase 3 FLAMES trial showed a benefit of progression-free survival with senaparib compared to placebo in patients with newly diagnosed, advanced ovarian cancer.